Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis
Autore:
Bes, A; Orgogozo, JM; Poncet, M; Rancurel, G; Weber, M; Bertholom, N; Calvez, R; Stehle, B;
Indirizzi:
Labs Rhone Poulenc Rorer, F-92545 Montrouge, France Labs Rhone Poulenc Rorer Montrouge France F-92545 2545 Montrouge, France Ctr Hosp Univ, Dept Neurol, Toulouse, France Ctr Hosp Univ Toulouse France Hosp Univ, Dept Neurol, Toulouse, France Ctr Hosp Univ, Dept Neurol, Bordeaux, France Ctr Hosp Univ Bordeaux France Hosp Univ, Dept Neurol, Bordeaux, France Ctr Hosp Univ, Dept Neurol, Marseille, France Ctr Hosp Univ Marseille France osp Univ, Dept Neurol, Marseille, France Ctr Hosp Univ, Dept Neurol, Paris, France Ctr Hosp Univ Paris FranceCtr Hosp Univ, Dept Neurol, Paris, France Ctr Hosp Univ, Dept Neurol, Nancy, France Ctr Hosp Univ Nancy FranceCtr Hosp Univ, Dept Neurol, Nancy, France
Titolo Testata:
EUROPEAN JOURNAL OF NEUROLOGY
fascicolo: 3, volume: 6, anno: 1999,
pagine: 313 - 322
SICI:
1351-5101(199905)6:3<313:A2DPMP>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
WHITE-MATTER LESIONS; LEUKO-ARAIOSIS; SENILE DEMENTIA; RISK-FACTORS; ABNORMALITIES; INTENSITY; LUCENCIES;
Keywords:
leukoaraiosis; computed tomography; cognitive functions; hypertension; elderly; nicergoline;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Bertholom, N Labs Rhone Poulenc Rorer, 15 Rue Vanne, F-92545 Montrouge, France Labs Rhone Poulenc Rorer 15 Rue Vanne Montrouge France F-92545
Citazione:
A. Bes et al., "A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis", EUR J NEUR, 6(3), 1999, pp. 313-322

Abstract

In this pilot study, 72 non-demented and non-depressive elderly hypertensive patients with evidence of leukoaraiosis on cerebral computed tomography scan (Rezek score: greater than or equal to 16) were randomly assigned to receive either nicergoline 30 mg b.i.d. (n = 36) or a placebo (n = 36) for 24 months. All patients received antihypertensives and their hypertension was controlled under treatment. They were evaluated by nine neuropsychological tests exploring memory, concentration, verbal and motor performances, administered at baseline and at every six-month interval during the study period. At baseline, the two groups n ere comparable for all demographic and clinical characteristics, including cognitive functions, except for the delayed recall of the Auditory Verbal Learning Test (AVLT), which was better in the placebo group (P = 0.04). Changes in scores over time were compared between the two groups. At the last visit, patients on nicergoline (n = 31) were found to have deteriorated less or to have improved more on test scores than the patients on placebo (n = 30), Significant differences n ere observed for memory function (AVLT short term recall, P = 0.026; AVLT delayed recall, P = 0.013; and, Benton Visual Retention Test, P = 0.002) and attentionand concentration (Letter Cancellation Test, P = 0.043; and, WAIS-R Digit Symbol subtest, P = 0.006). The Rezek score remained unchanged in the two groups. Tolerance of nicergoline was similar to that of placebo. In conclusion, this study shows that nicergoline 30 mg b.i.d. administered over a 24-month period attenuates the deterioration in cognitive functions in elderly hypertensive patients with leukoaraiosis. Whether these effects were specific for this type of white matter changes could not be determined in the contest of this pilot study. Eur J Neurol 6:313-322 (C) 1999 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 03:57:17